Bailard, Inc. Harpoon Therapeutics, Inc. Transaction History

Bailard, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 08, 2023	BUY	$0.65 - $1.37 $41,080 - $86,584	63,200 New	63,200 $46,000
Q3 2021 Nov 15, 2021	SELL	$7.88 - $14.0 $936,758 - $1.66 Million	-118,878 Closed	0 $0
Q2 2021 Aug 13, 2021	SELL	$13.81 - $23.25 $164,339 - $276,675	-11,900 Reduced 9.1%	118,878 $1.65 Million
Q1 2021 May 13, 2021	SELL	$17.65 - $24.16 $126,832 - $173,613	-7,186 Reduced 5.21%	130,778 $2.74 Million
Q4 2020 Feb 03, 2021	BUY	$12.83 - $17.84 $115,008 - $159,917	8,964 Added 6.95%	137,964 $2.29 Million
Q3 2020 Nov 10, 2020	BUY	$11.01 - $18.52 $280,755 - $472,260	25,500 Added 24.64%	129,000 $2.19 Million
Q2 2020 Aug 12, 2020	SELL	$11.11 - $24.72 $133,320 - $296,640	-12,000 Reduced 10.39%	103,500 $1.72 Million
Q1 2020 Apr 16, 2020	BUY	$10.74 - $16.32 $1.24 Million - $1.88 Million	115,500 New	115,500 $1.34 Million

353K

Ticker HARP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,106,800
Description
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candi...

Get notified when there are updates to the investment portfolio of Bailard, Inc., based on Form 13F filings with the SEC.

Stay updated on Bailard, Inc. with notifications on news.